Dear Reader: We are entering the festive last quarter of 2022 and Pharma Intelligence and the IPA wishes all members a sparkling and prosperous Diwali!
This edition of the newsletter features a crop of stories on hot topics. There’s a piece on biosimilar interchangeabilty and the need to clarify semantics around that designation in the US, while we also encapsulate investor advice for cell and gene therapy developers from fundraising and platform development to manufacturing.
We’ve also spotlighted certain niche partnering efforts as French firm Allecra scouts for a US commercialization ally for its complicated urinary tract infection asset.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Archana Jatkar - Associate Secretary General, IPA